Cargando…

Comparison of plasma prolactin and CEA in monitoring patients with adenocarcinoma of colon and rectum.

Plasma prolactin (PRL) and carcinoembryonic antigen (CEA) were measured by radioimmunoassay in 74 patients with adenocarcinoma of colon and rectum. The markers were correlated with disease stage, histological grade and progression/remission of disease. The circulating preoperative median PRL and CEA...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhatavdekar, J. M., Patel, D. D., Giri, D. D., Karelia, N. H., Vora, H. H., Ghosh, N., Shah, N. G., Trivedi, S. N., Balar, D. B.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1992
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977975/
https://www.ncbi.nlm.nih.gov/pubmed/1419646
_version_ 1782135377878843392
author Bhatavdekar, J. M.
Patel, D. D.
Giri, D. D.
Karelia, N. H.
Vora, H. H.
Ghosh, N.
Shah, N. G.
Trivedi, S. N.
Balar, D. B.
author_facet Bhatavdekar, J. M.
Patel, D. D.
Giri, D. D.
Karelia, N. H.
Vora, H. H.
Ghosh, N.
Shah, N. G.
Trivedi, S. N.
Balar, D. B.
author_sort Bhatavdekar, J. M.
collection PubMed
description Plasma prolactin (PRL) and carcinoembryonic antigen (CEA) were measured by radioimmunoassay in 74 patients with adenocarcinoma of colon and rectum. The markers were correlated with disease stage, histological grade and progression/remission of disease. The circulating preoperative median PRL and CEA levels were significantly higher in colorectal cancer patients than in their respective controls. PRL was elevated in all Dukes stages and in all histological grades of the tumour whereas the rise in CEA was more pronounced in Dukes D. Out of 74 patients, 29% (21/74) developed recurrent disease and 31% (23/74) responded to the treatment. With regard to monitoring recurrence(s), the predictive value of PRL was 94% which was significantly greater than that of CEA which was only 62%. In patients who developed liver metastases PRL remained elevated whereas CEA showed more than 100-fold increase. Therefore, we feel that CEA is a better marker for monitoring patients who developed liver metastases. From our results, we suggest that PRL can be used as a better overall marker for detecting recurrence(s) in patients with colorectal adenocarcinoma.
format Text
id pubmed-1977975
institution National Center for Biotechnology Information
language English
publishDate 1992
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-19779752009-09-10 Comparison of plasma prolactin and CEA in monitoring patients with adenocarcinoma of colon and rectum. Bhatavdekar, J. M. Patel, D. D. Giri, D. D. Karelia, N. H. Vora, H. H. Ghosh, N. Shah, N. G. Trivedi, S. N. Balar, D. B. Br J Cancer Research Article Plasma prolactin (PRL) and carcinoembryonic antigen (CEA) were measured by radioimmunoassay in 74 patients with adenocarcinoma of colon and rectum. The markers were correlated with disease stage, histological grade and progression/remission of disease. The circulating preoperative median PRL and CEA levels were significantly higher in colorectal cancer patients than in their respective controls. PRL was elevated in all Dukes stages and in all histological grades of the tumour whereas the rise in CEA was more pronounced in Dukes D. Out of 74 patients, 29% (21/74) developed recurrent disease and 31% (23/74) responded to the treatment. With regard to monitoring recurrence(s), the predictive value of PRL was 94% which was significantly greater than that of CEA which was only 62%. In patients who developed liver metastases PRL remained elevated whereas CEA showed more than 100-fold increase. Therefore, we feel that CEA is a better marker for monitoring patients who developed liver metastases. From our results, we suggest that PRL can be used as a better overall marker for detecting recurrence(s) in patients with colorectal adenocarcinoma. Nature Publishing Group 1992-11 /pmc/articles/PMC1977975/ /pubmed/1419646 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Bhatavdekar, J. M.
Patel, D. D.
Giri, D. D.
Karelia, N. H.
Vora, H. H.
Ghosh, N.
Shah, N. G.
Trivedi, S. N.
Balar, D. B.
Comparison of plasma prolactin and CEA in monitoring patients with adenocarcinoma of colon and rectum.
title Comparison of plasma prolactin and CEA in monitoring patients with adenocarcinoma of colon and rectum.
title_full Comparison of plasma prolactin and CEA in monitoring patients with adenocarcinoma of colon and rectum.
title_fullStr Comparison of plasma prolactin and CEA in monitoring patients with adenocarcinoma of colon and rectum.
title_full_unstemmed Comparison of plasma prolactin and CEA in monitoring patients with adenocarcinoma of colon and rectum.
title_short Comparison of plasma prolactin and CEA in monitoring patients with adenocarcinoma of colon and rectum.
title_sort comparison of plasma prolactin and cea in monitoring patients with adenocarcinoma of colon and rectum.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977975/
https://www.ncbi.nlm.nih.gov/pubmed/1419646
work_keys_str_mv AT bhatavdekarjm comparisonofplasmaprolactinandceainmonitoringpatientswithadenocarcinomaofcolonandrectum
AT pateldd comparisonofplasmaprolactinandceainmonitoringpatientswithadenocarcinomaofcolonandrectum
AT giridd comparisonofplasmaprolactinandceainmonitoringpatientswithadenocarcinomaofcolonandrectum
AT karelianh comparisonofplasmaprolactinandceainmonitoringpatientswithadenocarcinomaofcolonandrectum
AT vorahh comparisonofplasmaprolactinandceainmonitoringpatientswithadenocarcinomaofcolonandrectum
AT ghoshn comparisonofplasmaprolactinandceainmonitoringpatientswithadenocarcinomaofcolonandrectum
AT shahng comparisonofplasmaprolactinandceainmonitoringpatientswithadenocarcinomaofcolonandrectum
AT trivedisn comparisonofplasmaprolactinandceainmonitoringpatientswithadenocarcinomaofcolonandrectum
AT balardb comparisonofplasmaprolactinandceainmonitoringpatientswithadenocarcinomaofcolonandrectum